Augustina Isioma Ikusemoro: Why Plasma and RBC Transfusions Follow Different Compatibility Rules
Augustina Isioma Ikusemoro, Hematology and Transfusion Medicine Specialist at Sharjah Blood Transfusion and Research Center, shared a post on LinkedIn:
“The wrong blood product can turn a life-saving transfusion into a life-threatening mistake.
ABO compatibility is not just laboratory science – it is patient safety.
One of the most misunderstood areas in transfusion medicine is this:
RBC compatibility and plasma compatibility are not the same.
For Red Blood Cells (RBCs):
We avoid giving antigens the patient does not have.
- Group O – universal RBC donor
- Group AB – universal RBC recipient
But for Plasma (FFP):
The rule is reversed.
- Group AB plasma – universal plasma donor
- Group O patients – can receive plasma from all groups
And what happens in emergencies when AB plasma is unavailable for an AB patient?
Clinical judgment matters.
Low-titer Group A plasma may be the preferred alternative.
Low-titer Group O plasma may be used as a last resort.
Group B plasma should generally be avoided.
The key lesson?
Knowing compatibility saves lives.
Because in transfusion medicine:
Right patient. Right product. Right time.
Not all blood products follow the same compatibility rules – and understanding the difference can prevent avoidable transfusion reactions.
Signature of Blood Doki. Educate. Empower. Elevate. Better blood. Better care. Better outcomes.”

Other posts featuring Augustina Isioma Ikusemoro on Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series